Yanan Zhu
Stock Analyst at Wells Fargo
(1.91)
# 3,112
Out of 4,918 analysts
65
Total ratings
36.54%
Success rate
-6.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $65 → $48 | $17.10 | +180.70% | 5 | Jul 24, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $2.30 | +595.65% | 3 | May 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $50 → $45 | $12.20 | +268.85% | 7 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $1 | $0.08 | +1,161.03% | 3 | May 14, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $19.12 | +266.11% | 3 | May 7, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $2.38 | +152.10% | 3 | Mar 21, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.21 | +211.53% | 2 | Mar 12, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.06 | +277.36% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $13.77 | +117.86% | 2 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $60 → $50 | $12.12 | +312.54% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $2.56 | +56.25% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $32 | $10.71 | +198.93% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $43.45 | +77.22% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $16.13 | +148.06% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $59.59 | +9.08% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.82 | +685.34% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $2.83 | +783.39% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $37.34 | +33.90% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.54 | +647.66% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.02 | +14,800.66% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.71 | +269.00% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $690.32 | -52.78% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
Jul 24, 2025
Maintains: Overweight
Price Target: $65 → $48
Current: $17.10
Upside: +180.70%
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $2.30
Upside: +595.65%
Arcturus Therapeutics Holdings
May 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.20
Upside: +268.85%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.08
Upside: +1,161.03%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $19.12
Upside: +266.11%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $2.38
Upside: +152.10%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.21
Upside: +211.53%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.06
Upside: +277.36%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $13.77
Upside: +117.86%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $12.12
Upside: +312.54%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $2.56
Upside: +56.25%
Nov 12, 2024
Maintains: Overweight
Price Target: $136 → $32
Current: $10.71
Upside: +198.93%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $43.45
Upside: +77.22%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $16.13
Upside: +148.06%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $59.59
Upside: +9.08%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.82
Upside: +685.34%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $2.83
Upside: +783.39%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $37.34
Upside: +33.90%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.54
Upside: +647.66%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.02
Upside: +14,800.66%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.71
Upside: +269.00%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $690.32
Upside: -52.78%